Featured Articles in the Current Issue
Potential exists to slow or prevent disease progression.
Targeting VEGF-A and Ang2 has effect greater than targeting either alone.
A proliferation of clinical trials means hope for patients.
- Gene Therapy Implications for Retina Specialists
- The Port Delivery System With Ranibizumab
- Prefilled Syringe Delivery of Intravitreal Anti-VEGF Medications
- UPFRONT: The Upsurge in Gene Therapy Trials
- SUBSPECIALTY NEWS: Angiogenesis meeting highlights, elevated IOP after intravitreal injection, and more.
- FUTURE FILE: Early data on promising new treatments for retinal disease.
- CLINICAL TRIAL DOWNLOAD: Two-Year Brolucizumab Data
- CODING Q&A: Challenges in Remote Screening of Diabetic Patients
- RETINA CONVERSATIONS: A Conversation With Evangelos S. Gragoudas, MD
- NEW PRODUCT APPLICATIONS: The Newest Frontier in Microperimetry
- CLINICAL TRIAL UPDATE